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Abstract
Catecholamine-producing tumors may arise in the adrenal medulla (pheochromocytomas) or in
extraadrenal chromaffin cells (secreting paragangliomas). Their prevalence is about 0.1% in patients
with hypertension and 4% in patients with a fortuitously discovered adrenal mass. An increase in
the production of catecholamines causes symptoms (mainly headaches, palpitations and excess
sweating) and signs (mainly hypertension, weight loss and diabetes) reflecting the effects of
epinephrine and norepinephrine on α- and β-adrenergic receptors. Catecholamine-producing
tumors mimic paroxysmal conditions with hypertension and/or cardiac rhythm disorders, including
panic attacks, in which sympathetic activation linked to anxiety reproduces the same signs and
symptoms. These tumors may be sporadic or part of any of several genetic diseases: familial
pheochromocytoma-paraganglioma syndromes, multiple endocrine neoplasia type 2,
neurofibromatosis 1 and von Hippel-Lindau disease. Familial cases are diagnosed earlier and are
more frequently bilateral and recurring than sporadic cases. The most specific and sensitive
diagnostic test for the tumor is the determination of plasma or urinary metanephrines. The tumor
can be located by computed tomography, magnetic resonance imaging and
metaiodobenzylguanidine scintigraphy. Treatment requires resection of the tumor, generally by
laparoscopic surgery. About 10% of tumors are malignant either at first operation or during follow-
up, malignancy being diagnosed by the presence of lymph node, visceral or bone metastases.
Recurrences and malignancy are more frequent in cases with large or extraadrenal tumors.
Patients, especially those with familial or extraadrenal tumors, should be followed-up indefinitely.
Definition, disease name and synonyms
Pheochromocytomas (PH) are neoplasms of chromaffin
tissue which synthesize catecholamines. Most of these
tumors appear in the adrenal medulla. Ten percent of cat-
echolamine-producing tumors arise from extraadrenal
chromaffin tissue and are called extraadrenal PH or secret-
ing paragangliomas (PGL). In decreasing order of fre-
quency, secreting PGL may develop in the Zuckerkandl
body, a vestigial chromaffin ganglion located at the root
of the upper mesenteric artery, in the sympathetic plexus
of the urinary bladder, the kidneys and the heart, or in
sympathetic ganglia in the mediastinum, the head or the
neck. Most head and neck PGL are non-secreting. Patients
with von Hippel Lindau (VHL) disease or familial PGL
(see below) may have uni- or bilateral PH, or PH plus
secreting or non-secreting PGL [1,2].
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Diagnostic criteria
PH and secreting PGL are defined by the synthesis and/or
secretion of catecholamines: dopamine, norepinephrine
and/or epinephrine. Catecholamines are partly or totally
converted within the tumor by catechol-O-methyltrans-
ferase into inactive metabolites, metanephrine and
normetanephrine. Consequently, the release of active cat-
echolamines into the circulation may be modest, absent
or paroxysmal. The presence of a catecholamine-produc-
ing tumor is nevertheless established by the presence of
high concentrations of metanephrine or normetane-
phrine in the plasma or in the urine [2,3].
Epidemiology
The prevalence of diagnosed cases of PH and PGL in
patients with hypertension and in those with adrenal inci-
dentalomas is about 1 per 1,000 [2] and 4% [4], respec-
tively. The incidence in the general population is
estimated to be 1 per 100,000 persons per year or less [1].
The whole-life incidence of PH and PGL is high in familial
syndromes with these tumors: 1–5% in neurofibromato-
sis type 1 (NF1), 15–20% in VHL, 30–50% in multiple
endocrine neoplasia type 2 (MEN-2) [2], and probably
more than 50% in SDHB and SDHD gene mutation carri-
ers [5,6].
Clinical description
The increased production of catecholamines by PH and
secreting PGL causes symptoms (mainly headaches, palpi-
tations and excess sweating) and signs (mainly hyperten-
sion, weight loss and diabetes) that reflect the effects of
catecholamines on α- and β-adrenergic receptors. Signs
and symptoms are variable and frequently paroxysmal
due to the variable and disorderly release of catecho-
lamines by the tumor. The typical presentation is a com-
bination of variable hypertension with paroxysmal
symptoms, either occurring spontaneously or provoked
by abdominal hyperpression during anteflexion, micturi-
tion or defecation [3].
Diagnosis of PH/PGL may be delayed for several reasons.
First, these tumors are rare. Second, hypertension may be
absent for long periods as active catecholamines can be
converted into biologically inactive metanephrines within
the tumor [1,3]. Third, the symptoms and signs are non-
specific, and common to both tumoral (in PH/PGL) and
neuronal (during stress) release of catecholamines. This
explains why the average time lag from the onset of hyper-
tension when present to the diagnosis of the tumor is
three years. Indeed, the tumor is often discovered fortui-
tously during diagnostic testing for symptoms or clinical
conditions not related to adrenal disease. Presymptomatic
diagnosis during the exploration of incidentally discov-
ered adrenal masses, the so-called incidentalomas, cur-
rently accounts for 25% of all cases [7]. Presymptomatic
diagnosis is also possible in patients with phenotypic evi-
dence or a family history of a genetic disease that is asso-
ciated with PH/PGL (see below).
Etiology
The etiology of tumorigenesis in PH and secreting PGL is
unknown, although valuable information has recently
been provided by work on the genomics of familial dis-
eases including these tumors. Normal regulation of the
RET protein, a tyrosine kinase receptor, is essential for the
development of sympathetic neurons. The constitutive
activation of RET by germ-line (in MEN-2) or somatic (in
a minority of sporadic PH) mutations activates various
signaling pathways involved in the development of
human neuroendocrine tumors including PH [8]. Func-
tional studies of succinate dehydrogenase (SDH)- or
mitochondrial complex II-dysfunction in familial PGL
have shown a link between carcinogenesis and alterations
in SDH subunits B and D. In hereditary cases with germ-
line SDHD or SDHB mutations, the tumors exhibit loss of
the remaining wild-type allele with complete inhibition
of complex II electron transfer activity, leading to activa-
tion of pro-angiogenic hypoxic-inducible transcription
factors (HIFs) [9-11]. The VHL tumor suppressor protein
(pVHL) also interacts with HIF after post-translational
prolyl-hydroxylation. In the absence of pVHL, HIF
becomes stabilized and is free to induce the expression of
several target genes that regulate angiogenesis and cell
growth [12]. When SDH is inhibited, the accumulation of
succinate seems to inhibit the prolyl-hydroxylation of HIF
and induce, as in VHL disease, an inappropriate stabiliza-
tion of HIF [13].
The hypertension associated with PH is primarily due to
increased total peripheral resistance. The mechanism of
this increase in resistance would seem to be straightfor-
ward because noradrenaline, secreted by the majority of
PH, is a potent vasoconstrictor through stimulation of α-
adrenergic receptors. However, when plasma catecho-
lamines are measured in subjects with PH, the correlation
between blood pressure (BP) and circulating noradrena-
line levels is poor. Several explanations for this poor cor-
relation have been proposed, including the simultaneous
release of noradrenaline and of the vasodilator dopamine,
variations in the inactivation of adrenaline and noradren-
aline by conjugation, the down-regulation of α-adrenergic
receptors, and, in some patients with PH, the concomitant
release by the tumor of neuropeptide Y and catecho-
lamines [1,2].
Diagnostic methods
Biochemical investigation for PH/PGL is generally con-
fined to hypertensive patients reporting bouts of head-
aches, palpitations and sweating, those with hypertension
resistant to treatment, and those with incidentalomas orOrphanet Journal of Rare Diseases 2006, 1:49 http://www.OJRD.com/content/1/1/49
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with a familial disease that predisposes to PH and/or PGL.
Positive diagnosis of PH and secreting PGL is chiefly
based on the quantification of plasma or urinary metane-
phrines, as this test is more sensitive than both the quan-
tification of urinary vanillyl-mandelate acid or plasma
catecholamines [2,3,14-16], and plasma neuropeptide Y
or chromogranin A determinations [17,18]. The determi-
nation of fractionated catecholamines (epinephrine and
norepinephrine) or catecholamine metabolites (metane-
phrine and normetanephrine) increases diagnostic sensi-
tivity [15] and provides a prognostic indicator: a low ratio
of epinephrine to total catecholamines or of metane-
phrine proper to total metanephrines is associated with
immature tumors, particularly extraadrenal or malignant
tumors [19,20]. Patients undergoing biochemical tests for
PH/PGL should be given instructions to obtain an accu-
rate 24-hour collection of acidified urines (for urinary
tests) and to avoid tricyclic antidepressants and paraceta-
mol for 5 days as these medications induce false positive
results in plasma metanephrine tests [3]. With accurate
plasma and urinary assays readily available, there is little
need to subject patients to the hazards of pharmacological
provocative tests. Paroxysmal conditions with hyperten-
sion and/or cardiac rhythm disorders mimic catecho-
lamine-secreting tumors, particularly panic attacks in
which sympathetic activation linked to anxiety repro-
duces the signs and symptoms of PH. Plasma and urinary
metanephrine concentrations are usually normal [2] and
the clonidine suppression test is a safe and effective means
of excluding a tumor in these conditions.
The purpose of pre-operative imaging tests is to locate the
tumor, ascertain whether it is single or multiple, adrenal
or ectopic, benign or malignant, and isolated or present
with other neoplasms in the context of familial syn-
dromes. Of 192 patients referred for the preoperative
work-up of a first PH or PGL, 20 (10%) had bilateral PH
and 25 had PGL (13%). Eleven PH and three PGL were
malignant (7% of all tumors). Tumors arose in the context
of a familial disease in 34 patients (18%), most of whom
had associated non-chromaffin tumors [7]. The combina-
tion of anatomical imaging studies using computed tom-
ography (CT) or magnetic resonance imaging (MRI) and
functional imaging studies (nuclear medicine) yields a
sensitivity of nearly 100% for diagnosing catecholamine-
producing tumors [21]. CT is the most commonly used
anatomical imaging technique but MRI is preferred for
children and pregnant patients. Functional imaging using
[123I] metaiodobenzylguanidine (MIBG) should be per-
formed where available, [131I]MIBG scintigraphy having a
lower sensitivity. Labetalol and antipsychotic drugs
should be withdrawn for several days before the investiga-
tions as they reduce [123I]MIBG and [131I]MIBG uptake.
Where these imaging methods give negative (mostly in
non-secreting PGL) or discordant results, the investigation
should be completed by scintigraphy with nonspecific lig-
ands such as somatostatin receptor scintigraphy or
[18F]fluorodeoxyglucose PET, fluoro-DOPA or fluoro-
dopamine PET. In addition to the primary tumor, CT, MRI
or scintigraphy may disclose lymph node, bone, liver or
pulmonary metastases, thereby establishing the presence
of a malignant PH or PGL.
Differential diagnosis
Catecholamine-secreting tumors mimic paroxysmal con-
ditions with hypertension and/or cardiac rhythm disor-
ders, particularly panic attacks in which sympathetic
activation linked to anxiety reproduces the signs and
symptoms of PH. Plasma and urinary metanephrine con-
centrations are usually normal in these conditions [2].
Acute cardiovascular events, such as myocardial infarc-
tion, pulmonary edema and stroke, also induce an
increase in catecholamine levels that may be sustained for
several days and associated with a rise in plasma or uri-
nary metanephrine concentration. The diagnosis of PH or
secreting PGL is excluded in these cases by the normaliza-
tion of metanephrines ten days after the onset of the event
[14]. Adrenomedullary hyperplasia, sometimes present in
patients with MEN-2, is distinguished from PH proper by
the absence of tumor. Non-secreting PGL can be differen-
tiated from secreting PGL by normal concentrations of
catecholamines and metanephrines in the plasma and
urine. Patients with hereditary PGL or with VHL disease
may harbor both secreting and non-secreting PGL, mak-
ing the differential diagnosis of the individual tumor dif-
ficult.
Genetic counseling
Prior to 2000, three different familial and syndromic dis-
eases were known to result in PGL and/or PH: MEN-2
induced by germline inactivating mutations in the RET
proto-oncogene; VHL disease due to mutations in the
tumor suppressor gene VHL; and NF1 caused by muta-
tions in the NF1 gene. More recently, the identification of
mutations in the SDH (SDHD, SDHB, SDHC) genes in
hereditary PGL and PH [22] has led to changes in the
genetic counseling and work-up for affected patients
[5,23-25].
Genetic testing is indicated for all patients with PGL and/
or PH, whatever the location of the tumor and the age of
the subjects, but such testing may also be indicated by
clinical and familial features (Figure 1). Targeted genetic
testing should be proposed to patients with phenotypic
clues and/or familial history for MEN-2 (medullary thy-
roid cancer, hyperparathyroidism), VHL disease (heman-
gioblastoma, renal or pancreatic tumors), or hereditary
PGL (head and neck PGL, familial history in the paternal
branch). The family pedigree may also direct the genetic
testing. The disease displays autosomal dominant inherit-Orphanet Journal of Rare Diseases 2006, 1:49 http://www.OJRD.com/content/1/1/49
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ance for all PH susceptibility genes but in families with
SDHD mutations the disease is transmitted exclusively via
the fathers due to genomic maternal imprinting. In
patients with an apparently sporadic presentation, the
VHL and SDHB genes should be analyzed in first. In carri-
ers of SDHB mutations, the resulting tumor is usually a
secreting or non-secreting PGL, which may be malignant
[4,24,26]. The identification of a causative mutation in
one affected patient should lead to presymptomatic
genetic testing of the family because the early detection of
small tumors in individuals determined to be at risk
would reduce the morbidity of the disease. Presympto-
matic genetic testing should be offered to all first-degree
relatives if a causative mutation is detected in the index
case.
Management
Pre-operative management
BP should be normalized whenever possible before sur-
gery because the incidence of perioperative complications
is consistently and independently linked to preoperative
BP [27]. The control of BP requires α- and β-adrenergic
antagonists. As the majority of PH and PGL secrete pre-
dominantly the α-agonist norepinephrine, α-adrenergic
antagonists are the cornerstone of hypertensive control.
Non-competitive α-blockers such as phenoxybenzamine
bind covalently to α-receptors producing an irreversible
blockade and a reflex tachycardia due to the inhibition of
presynaptic  α2-adrenergic receptors. They are therefore
useful for prolonged antihypertensive treatment of malig-
nant PH/PGL but should be avoided pre-operatively
because they increase the risk of acute hypotension during
tumor removal and the immediate post-operative period.
Selective α1-blockers such as prazosine or its derivative
doxazosine are more suitable because they have a shorter
duration of action and do not produce α2-anti-adrenergic-
mediated tachycardia. The first dose of prazosine may
induce a sharp drop in BP, and therefore the dose should
be increased progressively from 0.5 to 5 mg tid. Alpha-
adrenergic blockade generally gives rise to tachycardia,
secondary to catecholamine β-receptor stimulation. This
requires the subsequent addition of a β-blocker. When
adrenergic blockade is insufficient, antihypertensive ther-
apy may be completed by administering a dihydropyrid-
ine and/or an angiotensin-converting enzyme inhibitor.
In view of the variability of BP in PH, it may be useful to
document the response to antihypertensive treatment
with a 24-hour ambulatory BP monitor. Prevention of
arrhythmias is based on β-blockade and careful correction
of hypokalemia: PH causes a state of secondary hyperal-
dosteronism, resulting in increased potassium loss.
Anesthesia and surgical management
Large variations in BP and cardiac rhythm may be
expected during the anesthetic management of patients
with PH, particularly during induction, intubation, peri-
toneal incision, and tumor handling and devasculariza-
tion. Radial artery pressure, pulmonary artery pressure
through a Swan-Ganz catheter, and electrocardiogram
(ECG) should be monitored continuously. Infusions of
short-acting vasodilator or anti-arrhythmic agents should
be prepared in advance and begun as soon as necessary.
Genetic testing in patients with pheochromocytomas and secreting paragangliomas (Adapted from [24]) Figure 1
Genetic testing in patients with pheochromocytomas and secreting paragangliomas (Adapted from [24]).Orphanet Journal of Rare Diseases 2006, 1:49 http://www.OJRD.com/content/1/1/49
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Laparoscopic surgery has supplanted the use of open sur-
gery in the management of most PH and intraabdominal
PGL. Adrenocortical-sparing surgery may be performed
using laparoscopy in patients with hereditary forms of PH
[28].
Post-operative and long term follow-up
Biochemical evidence for the cure of the tumor cannot be
obtained immediately: the output of catecholamine
metabolites remains high, albeit decreasing, during the
first week following tumor resection. This output repre-
sents the emptying of extratumoral pools of catecho-
lamines and should not be interpreted as only partial
response to surgery. The normalization of plasma or uri-
nary metanephrine concentration should be checked 10
days after surgery. If the metanephrine concentrations
remain high, [123I]MIBG scintigraphy should be per-
formed and may disclose distant metastases whose MIBG
uptake was masked pre-operatively by the primary
tumor's higher metabolic activity.
As PH and PGL can recur, patients operated for PH/PGL
should have a life-long follow-up, the minimum annual
checks including BP measurement and plasma or urinary
metanephrine determination. In a cohort of patients oper-
ated upon for PH or PGL, the 10-year probability of recur-
rence (defined as the reappearance of the disease after
eradication of the tumor had been confirmed by negative
biochemical and imaging tests) was 16% [7]. Patients
with recurrences were younger, had larger tumors, and
Algorithm for the initial management and long term follow-up in patients with pheochromocytomas and secreting paraganglio- mas Figure 2
Algorithm for the initial management and long term follow-up in patients with pheochromocytomas and secreting paraganglio-
mas.Orphanet Journal of Rare Diseases 2006, 1:49 http://www.OJRD.com/content/1/1/49
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were more likely to have familial disease and/or bilateral,
or extra-adrenal PGL than patients with no recurrence.
Recurrences were malignant in one patient out of two.
Malignant PH/PGL is compatible with prolonged survival
with symptom-free intervals varying from months to dec-
ades. Factors associated with a longer survival seem to be
an early diagnosis and excision of the primary tumor, and,
whenever possible, aggressive excision of any recurrence
or soft-tissue metastases. When recurrences are small with
an accessible vascular pedicle, surgical excision may be
preceded, or replaced, by therapeutic embolization. In
cases where soft-tissue or skeletal metastases are too wide-
spread to make surgery or embolization feasible, several
palliative therapies may be considered. Pharmacologic
treatment aimed at the long-term blockade of catecho-
lamine synthesis with α-methyl-p-tyrosine may allow a
good quality of life but does not affect tumor progression.
Conventional radiotherapy may provide good palliation
in cases of painful metastases. Metabolic radiotherapy
with [131I]MIBG and chemotherapy may provide clinical,
hormonal and sometimes tumoral improvement [29].
Such therapies have only been evaluated in limited
uncontrolled trials and their effect on survival is not
known. They should therefore only be considered after
the surgical excision of primary or recurrent tumors.
Unresolved questions
Current research aims to unravel the etiology of sporadic
PH and PGL; to develop tumor-mass markers for PGL
with little or no catecholamine synthesis; to assess geno-
type-phenotype relationships and disease penetrance in
rare familial diseases; and to design trials of adjuvant ther-
apies or alternatives to surgery for aggressive tumors.
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